Scholarlink

<p>This retrospective study evaluated changes in lesion bone density and volume in medication-related osteonecrosis of the jaw (MRONJ) using cone-beam computed tomography (CBCT) at different disease stages following conservative and surgical treatment. Additionally, the study analyzed the correlations between these changes and influencing factors. A total of 54 patients (mean [SD] age, 75.43 [7.44] years) diagnosed with stage 0, 1, 2, or 3 MRONJ, according to the American Association of Oral and Maxillofacial Surgeons’ guidelines, were included. Pre- and post-treatment CBCT images were superimposed to identify the lesion locations, and lesions were segmented manually using ITK-SNAP software. Lesion mean bone density and volume before and after treatment were calculated. Stage 0–1 lesions showed a 16.8% reduction in bone density and a 17.0% reduction in volume and, while stage 2–3 lesions exhibited a 20.8% increase in bone density and a 46.0% reduction in volume (<i>P</i> &lt; 0.05). In conclusion, stage 2–3 lesions demonstrated better healing outcomes than stage 0–1 lesions. Notably, conservative treatment may potentially benefit from a longer drug holiday, while surgical treatment showed positive effects on both soft and hard tissues in stage 2–3 lesions, regardless of the drug holiday duration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stage-related changes of bone density and volume in treatment of medication-related osteonecrosis of the jaw

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Quang-Huy Nguyen,
  • Hieu Nguyen,
  • Hai-Van Giap,
  • Jeong Keun Lee

摘要

This retrospective study evaluated changes in lesion bone density and volume in medication-related osteonecrosis of the jaw (MRONJ) using cone-beam computed tomography (CBCT) at different disease stages following conservative and surgical treatment. Additionally, the study analyzed the correlations between these changes and influencing factors. A total of 54 patients (mean [SD] age, 75.43 [7.44] years) diagnosed with stage 0, 1, 2, or 3 MRONJ, according to the American Association of Oral and Maxillofacial Surgeons’ guidelines, were included. Pre- and post-treatment CBCT images were superimposed to identify the lesion locations, and lesions were segmented manually using ITK-SNAP software. Lesion mean bone density and volume before and after treatment were calculated. Stage 0–1 lesions showed a 16.8% reduction in bone density and a 17.0% reduction in volume and, while stage 2–3 lesions exhibited a 20.8% increase in bone density and a 46.0% reduction in volume (P < 0.05). In conclusion, stage 2–3 lesions demonstrated better healing outcomes than stage 0–1 lesions. Notably, conservative treatment may potentially benefit from a longer drug holiday, while surgical treatment showed positive effects on both soft and hard tissues in stage 2–3 lesions, regardless of the drug holiday duration.